# Revance Therapeutics Inc. (RVNC)

Source: https://www.quantisnow.com/company/RVNC
Generated: 2026-11-21T05:47:38.019Z

- Ticker: RVNC
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2014
- Website: revance.com

## About

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DAXI in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. for the development and regulatory approval of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Newark, California.

## Latest RVNC news and filings

- 2025-02-18 11:07 UTC [SEC Form 15-12G filed by Revance Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-revance-therapeutics-inc-5892605)
- 2025-02-13 21:02 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Revance Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-revance-therapeutics-inc-5887345)
- 2025-02-12 13:16 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Revance Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-revance-therapeutics-inc-5883518)
- 2025-02-12 13:08 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Revance Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-revance-therapeutics-inc-5883510)
- 2025-02-12 13:06 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Revance Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-revance-therapeutics-inc-5883508)
- 2025-02-12 13:04 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Revance Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-revance-therapeutics-inc-5883502)
- 2025-02-12 13:03 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Revance Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-revance-therapeutics-inc-5883500)
- 2025-02-12 13:02 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Revance Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-revance-therapeutics-inc-5883496)
- 2025-02-12 13:01 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Revance Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-revance-therapeutics-inc-5883492)
- 2025-02-12 13:00 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Revance Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-revance-therapeutics-inc-5883477)
- 2025-02-12 12:58 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Revance Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-revance-therapeutics-inc-5883435)
- 2025-02-12 12:57 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Revance Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-revance-therapeutics-inc-5883434)
- 2025-02-12 12:55 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Revance Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-revance-therapeutics-inc-5883432)
- 2025-02-12 12:54 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Revance Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-revance-therapeutics-inc-5883430)
- 2025-02-12 12:53 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Revance Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-revance-therapeutics-inc-5883429)
- 2025-02-12 12:52 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Revance Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-revance-therapeutics-inc-5883427)
- 2025-02-12 12:50 UTC [SEC Form POSASR filed by Revance Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-posasr-filed-by-revance-therapeutics-inc-5883424)
- 2025-02-11 17:16 UTC [SEC Form SCHEDULE 13G filed by Revance Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-revance-therapeutics-inc-5881531)
- 2025-02-07 20:46 UTC [Crown Laboratories Completes Acquisition of Revance Therapeutics](https://www.quantisnow.com/insight/crown-laboratories-completes-acquisition-of-revance-therapeutics-5877356)
- 2025-02-07 01:06 UTC [SEC Form 4] [Director Gangolli Julian S returned 15,000 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-gangolli-julian-s-returned-15000-shares-to-the-company-5876433)
- 2025-02-06 23:19 UTC [SEC Form SCHEDULE 13G filed by Revance Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-revance-therapeutics-inc-5876321)
- 2025-02-06 20:59 UTC [SEC Form 4] [President & CEO Foley Mark J returned 112,619 shares to the company and was granted 84,686 shares, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/president-ceo-foley-mark-j-returned-112619-shares-to-the-5875351)
- 2025-02-06 20:59 UTC [SEC Form 4] [CFO Schilke Tobin returned 124,438 shares to the company and was granted 20,883 shares, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/cfo-schilke-tobin-returned-124438-shares-to-the-company-and-5875348)
- 2025-02-06 20:58 UTC [SEC Form 4] [CLO & GC Moxie Dwight returned 114,104 shares to the company and was granted 18,125 shares, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/clo-gc-moxie-dwight-returned-114104-shares-to-the-company-5875347)
- 2025-02-06 20:58 UTC [SEC Form 4] [CMO & Global Therapeutics Lead Hollander David returned 95,212 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/cmo-global-therapeutics-lead-hollander-david-returned-95212-shares-to-5875343)
- 2025-02-06 20:57 UTC [SEC Form 4] [Chief Commercial Officer Jordan Erica returned 107,942 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-commercial-officer-jordan-erica-returned-107942-shares-to-the-5875338)
- 2025-02-06 20:56 UTC [SEC Form 4] [Director Ware Olivia C returned 15,000 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-ware-olivia-c-returned-15000-shares-to-the-company-5875335)
- 2025-02-06 20:56 UTC [SEC Form 4] [Director Kolaja Carey Oconnor returned 15,000 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-kolaja-carey-oconnor-returned-15000-shares-to-the-company-5875334)
- 2025-02-06 20:49 UTC [SEC Form 4] [Director Coric Vlad returned 15,000 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-coric-vlad-returned-15000-shares-to-the-company-closing-5875324)
- 2025-02-06 20:49 UTC [SEC Form 4] [Director Beraud Jill returned 15,000 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-beraud-jill-returned-15000-shares-to-the-company-closing-5875322)
- 2025-02-06 20:48 UTC [SEC Form 4] [Director Nolet Chris returned 15,000 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-nolet-chris-returned-15000-shares-to-the-company-closing-5875320)
- 2025-02-06 20:45 UTC [SEC Form 4] [Director Russell Angus C. returned 15,000 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-russell-angus-c-returned-15000-shares-to-the-company-5875316)
- 2025-02-06 14:22 UTC [SEC Form 25-NSE filed by Revance Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-revance-therapeutics-inc-5874953)
- 2025-02-06 13:59 UTC [SEC Form 8-K] [Revance Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update](https://www.quantisnow.com/insight/revance-therapeutics-inc-filed-sec-form-8-k-completion-of-acquisition-5874904)
- 2025-02-06 13:39 UTC [Mergers & Acquisitions] [Crown Laboratories Announces Completion of Acquisition of Revance Therapeutics](https://www.quantisnow.com/insight/crown-laboratories-announces-completion-of-acquisition-of-revance-therapeutics-5874849)
- 2025-02-06 00:53 UTC [SEC Form 4] [CEO Foley Mark J was granted 27,933 shares, increasing direct ownership by 3% to 1,024,868 units (SEC Form 4)](https://www.quantisnow.com/insight/ceo-foley-mark-j-was-granted-27933-shares-increasing-direct-5874116)
- 2025-02-06 00:53 UTC [SEC Form 4] [CLO & GC Moxie Dwight was granted 5,979 shares, increasing direct ownership by 4% to 143,794 units (SEC Form 4)](https://www.quantisnow.com/insight/clo-gc-moxie-dwight-was-granted-5979-shares-increasing-direct-5874115)
- 2025-02-06 00:53 UTC [SEC Form 4] [CFO Schilke Tobin was granted 6,888 shares, increasing direct ownership by 4% to 201,554 units (SEC Form 4)](https://www.quantisnow.com/insight/cfo-schilke-tobin-was-granted-6888-shares-increasing-direct-ownership-5874114)
- 2025-02-05 13:41 UTC [SEC Schedule 14D-9] [Amendment: SEC Form SC 14D9/A filed by Revance Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-14d9a-filed-by-revance-therapeutics-inc-5872011)
- 2025-02-05 13:00 UTC [Crown Laboratories and Revance Therapeutics Announce Expiration of Tender Offer](https://www.quantisnow.com/insight/crown-laboratories-and-revance-therapeutics-announce-expiration-of-tender-offer-5871907)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/RVNC
- Earnings history: https://www.quantisnow.com/earnings/RVNC
- Dividend history: https://www.quantisnow.com/dividends/RVNC
- Insider transactions: https://www.quantisnow.com/insiders/RVNC
- Options chain: https://www.quantisnow.com/options/RVNC
- SEC 8-K filings only: https://www.quantisnow.com/company/RVNC/8-k
- RSS and alerts for RVNC: https://www.quantisnow.com/docs/rss-feeds.md
